A Pivotal Phase III Study of BEKINDA (RHB-102) 12 mg for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Trial Profile

A Pivotal Phase III Study of BEKINDA (RHB-102) 12 mg for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 09 Apr 2018 According to a RedHill Biopharma media release, the company plans to meet with the FDA in the second quarter of 2018 to discuss the design of the trial.
    • 16 Jan 2018 According to a RedHill Biopharma media release, the company plans to meet with the FDA in the first half of 2018 to discuss the design of the trial.
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top